Kit, device, and method for detecting lung cancer

A method for detecting and treating or performing a diagnostic procedure for lung cancer, comprising:

• determining an expression level of hsa-miR-2467-3p in a sample from a human subject using a nucleic acid(s) capable of specifically binding to hsa-miR-2467-3p, or using a kit or device comprising a nucleic acid(s) capable of specifically binding to hsa-miR-2467-3p,
• wherein the determining comprises the following steps of:
• (a) contacting hsa-miR-2467-3p in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-2467-3p with the nucleic acid(s);
• (b) measuring an expression level of hsa-miR-2467-3p;
• (c) comparing the expression level of hsa-miR-2467-3p measured in the step (b) to a control expression level of hsa-miR-2467-3p in a control sample from a healthy human subject measured in the same way as in the step (b) to allow for diagnosis of lung cancer;
• (d) detecting an increased level of hsa-miR-2467-3p in the sample from the human subject as compared to the control expression level of hsa-miR-2467-3p from the sample from the human subject that does not have lung cancer, wherein the increased level of hsa-miR-2467-3p indicates that the human subject has lung cancer;
• and
• (e) treating the human subject having lung cancer or performing a diagnostic procedure on the human subject having lung cancer;
• wherein the sample is blood, serum, or plasma;
• wherein the treatment comprises chemotherapy, radiotherapy, immunotherapy, molecular targeted therapy, surgery or a combination thereof;
• and
• wherein the diagnostic procedure comprises an imaging test method selected from the group consisting of a chest X-ray examination, CT examination, MRI examination, and PET examination;
• a pathological examination method selected from the group consisting of sputum cytology, pleural fluid analysis, bronchoscopy, and percutaneous needle biopsy;
• or a combination thereof.